Last-Resort cancer drug made available to patients with no alternatives
NCT ID NCT06195514
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This expanded access program offers fruquintinib, a targeted cancer drug, to adults with metastatic colorectal cancer that has worsened after all standard treatments. Participants take the drug as a capsule daily for three weeks, then one week off. The goal is to provide access until the drug is commercially available or no longer helps.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Fruquintinib (a targeted cancer drug taken as a capsule)
- What this could lead to
- If it works, this could provide a treatment option for people with advanced colorectal cancer who have run out of standard therapies.
- What could go wrong
- This is an expanded access program, not a formal trial, so results are not systematically collected. The drug may not work for everyone and can have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk
- Can a smart digital program restore sleep for cancer survivors?
- Can a new infusion drug shrink Hard-to-Treat tumors?